https://www.pharmaradar360.com/article/0e6a59b5912c0800PharmaRadar360en2026-04-27T10:45:00.000ZLilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia verahttps://www.pharmaradar360.com/article/13870ee8e47ff13dPharmaRadar360en2026-04-27T10:39:33.000ZACRP 2026 Panelists Encourage Attendees to “Embrace the Now, Ignite What’s Next”https://www.pharmaradar360.com/article/068b74cebc797047PharmaRadar360en2026-04-27T09:35:23.000ZKOMENTARZ z okazji Światowego Dnia Własności Intelektualnej. prof. Rafał Sikorski, Uniwersytet im. Adama Mickiewicza w Poznaniuhttps://www.pharmaradar360.com/article/80f719e55bb0a4a2PharmaRadar360en2026-04-27T09:33:19.000ZΓενόσημα Φεβρουάριος 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/0dc848fc3b8cd966PharmaRadar360en2026-04-27T08:40:20.000ZLa AEMPS informa del cese de comercialización, retirada del mercado y recuperación de la tinta para tatuaje Dynamic Candy Apple Redhttps://www.pharmaradar360.com/article/c27e20b58bbef60fPharmaRadar360en2026-04-27T07:46:40.000ZAttention aux confusions entre flaconshttps://www.pharmaradar360.com/article/813aae91d272993ePharmaRadar360en2026-04-27T07:00:00.000ZTESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigationhttps://www.pharmaradar360.com/article/ac9f9c8c6c3d257dPharmaRadar360en2026-04-27T06:31:00.000ZFinancial Results of Astellas for FY2025https://www.pharmaradar360.com/article/e7c215493f02a97aPharmaRadar360en2026-04-27T06:30:00.000ZNotice Regarding Impairment Loss and Extraordinary Losses in Non-consolidated Financial Results(J-GAAP)https://www.pharmaradar360.com/article/e8a84c2c8afebd89PharmaRadar360en2026-04-27T06:30:00.000ZNotice of Nominees for Directorshttps://www.pharmaradar360.com/article/4d92c6974eb992b2PharmaRadar360en2026-04-27T06:30:00.000ZAstellas Announces Personnel Changehttps://www.pharmaradar360.com/article/36c516decf75d318PharmaRadar360en2026-04-27T03:00:00.000Z[ANZEN]PMDA Medical Safety Information: Use of Insulin-Specific Syringe- Incorrect dose may cause serious adverse health effects- postedhttps://www.pharmaradar360.com/article/81ba7e827d5a7f33PharmaRadar360en2026-04-27T03:00:00.000Z[YAKKYOKUKATA]Implementation of PDG harmonized texts into Japanese Pharmacopoeia (General Chapters) updatedhttps://www.pharmaradar360.com/article/80547f3614741d8dPharmaRadar360en2026-04-27T03:00:00.000Z[YAKKYOKUKATA]Implementation of PDG harmonized texts into Japanese Pharmacopoeia (Monographs) updatedhttps://www.pharmaradar360.com/article/e4db59030afe0b65PharmaRadar360en2026-04-27T03:00:00.000Z[KOKUSAI]Information on PMDA Asia Office updatedhttps://www.pharmaradar360.com/article/da329d28cc7916cePharmaRadar360en2026-04-27T02:30:00.000ZNotice regarding Withdrawal of Shelf Registration Statement for Issuance of New Shareshttps://www.pharmaradar360.com/article/fa6394ab504f4fedPharmaRadar360en2026-04-27T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/619476fa3e420899PharmaRadar360en2026-04-27T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/62a44a091128d3d0PharmaRadar360en2026-04-27T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/8bdd7b6dcf9bd2afPharmaRadar360en2026-04-27T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/6c91f934cf35491cPharmaRadar360en2026-04-27T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/452b48093a8b9f2bPharmaRadar360en2026-04-27T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/7a8dd409bd941792PharmaRadar360en2026-04-27T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/b1ce635f434d2223PharmaRadar360en2026-04-27T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/90de6a1cd71570bcPharmaRadar360en2026-04-27T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/1e6819024749be47PharmaRadar360en2026-04-27T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/aee96fbb2715bd76PharmaRadar360en2026-04-27T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/06e699f2112aeb04PharmaRadar360en2026-04-27T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/26fae5de315ea2bePharmaRadar360en2026-04-27T00:00:00.000Z6203https://www.pharmaradar360.com/article/c2b32e84244354c6PharmaRadar360en2026-04-27T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/beb7166503ff9b35PharmaRadar360en2026-04-26T17:00:00.000ZData at Heart Rhythm 2026 highlight key Boston Scientific therapieshttps://www.pharmaradar360.com/article/abf22637926e2301PharmaRadar360en2026-04-26T11:00:55.000Z“What Got Us Here, Won’t Get Us There,” and Other Insights on the Clinical Research Workforce Shared at ACRP 2026